DAB2IP and esophageal squamous cell carcinoma: In our study, we found that decreased expression of DAB2IP in ESCC patients treated with definitive chemoradiotherapy correlated positively with ESCC resistance to CRT and was a strong and independent predictor for short disease-specific survival (DSS) of ESCC patients.